[1]刘晴晴,康锦花,龙文杰,等.基于网络药理学探讨“金银花-连翘”药对防治新型冠状病毒肺炎的作用机制[J].西部中医药,2023,36(06):19-25.[doi:10.12174/j.issn.2096-9600.2023.06.05]
　LIU Qingqing,KANG Jinhua,LONG Wenjie,et al.The Mechanism of Preventing and Treating COVID-19 with JinYinhua-Lianqiao Couplet Medicinals Based on Network Pharmacology[J].Western Journal of Traditional Chinese Medicine,2023,36(06):19-25.[doi:10.12174/j.issn.2096-9600.2023.06.05]
点击复制

基于网络药理学探讨“金银花-连翘”药对防治新型冠状病毒肺炎的作用机制
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
36
期数:
2023年06期
页码:
19-25
栏目:
出版日期:
2023-06-15

文章信息/Info

Title:
The Mechanism of Preventing and Treating COVID-19 with JinYinhua-Lianqiao Couplet Medicinals Based on Network Pharmacology
作者:
刘晴晴1, 康锦花1, 龙文杰2, 宁怡乐2, 王陵军2, 杨忠奇2
1.广州中医药大学第一临床医学院，广东 广州 510405
2.广州中医药大学第一附属医院，广东 广州 510405
Author(s):
LIU Qingqing1, KANG Jinhua1, LONG Wenjie2, NING Yile2, WANG Lingjun2, YANG Zhongqi2
1.First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
2.The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China
关键词:
新型冠状病毒肺炎; “金银花-连翘”药对; 网络药理学
Keywords:
COVID-19; "" couplet medicinals; network pharmacology
分类号:
R563.1
DOI:
10.12174/j.issn.2096-9600.2023.06.05
文献标志码:
A
摘要:
目的利用网络药理学的技术和方法探索“金银花-连翘”（简称“银翘”）药对对防治新型冠状病毒肺炎（coronavirus disease 2019，COVID-19）作用的活性成分及其作用机制。 方法通过中药系统药理学分析平台（traditional Chinese medicine system pharmacology，TCMSP）根据口服生物利用度（oral bioavailability，OB）和类药性（drug-likeness，DL）检索中药“金银花”“连翘”中的化学成分和作用靶点，并在人类基因数据库（genecards：the human gene database）数据库中寻找“novel coronavirus pneumonia”的相关靶点，将“银翘”药对作用靶点与COVID-19相关靶点进行映射分析，筛选“银翘”药对防治COVID-19的活性成分和作用靶点。并用Cytoscape 3.7.2软件建立“中药活性成分-作用靶点-疾病”网络、通过STRING平台构建蛋白相互作用（protein-protein interaction，PPI）网络、通过DAVID分析平台，对靶点基因GO富集分析和KEGG代谢通路进行分析，探究“银翘”药对防治COVID-19的作用机制。 结果从“金银花”中筛选化合物23个，“连翘”中化合物23个，二者有效作用靶点204个，通过Venn图获得与COVID-19有关的作用靶点44个，PPI网络发现IL-6、IL-1B、MAPK1、MAPK8、CXCL8、RELA、CCL2、IL10、ICAM1、IL-2、PTGS2、CASP3、MAPK14、STAT1、EGFR、FOS、IL-4等可能是“银翘”药对防治COVID-19的作用靶点。GO功能分析发现79个条目，涉及转录因子活性、受体活性、细胞因子活性、酶活性及生物合成过程的调控等方面。KEGG通路分析发现44个疾病药物交集靶点显著富集在146条通路上（P＜0.01），涉及炎症、免疫、凋亡、自噬、激素代谢、肿瘤等方面，通路包括糖尿病并发症中的AGE-RAGE信号通路、IL-17信号通路、TNF信号通路、Toll样受体信号通路、C型凝集素受体信号通路、HIF-1信号通路、NF-κB信号通路、NOD样受体信号通路等经典信号通路，此外还参与细菌或病毒感染通路，如甲型流感、丙肝、百日咳、结核、巨细胞病毒感染、EB病毒感染等。这些作用通路可能是“银翘”药对防治COVID-19的依据。 结论初步验证了“银翘”药对防治COVID-19的作用机制，“银翘”药对相须配伍具有多个活性成分，能通过多个靶点、多个通路以发挥抗病毒、抑菌抗炎、调节免疫作用来防治COVID-19。
Abstract:
ObjectiveTo explore the active ingredients of "Yinqiao" couplet medicinals in the prevention and treatment of COVID-19 by utilizing the technology and methods of network pharmacology and its mechanism. MethodsChemical ingredients and targets of "Jinyinhua(Lonicera japonica)" and "Lianqiao (Forsythia suspensa)" were searched according to OB and DL via TCMSP, and the related targets of "novel coronavirus pneumonia" were surveyed from genecards, mapping analysis between the targets of "Jinyinhua-Lianqiao" and the targets related to COVID-19 was carried out to screen the active ingredients and the targets of "Yinqiao" couplet medicinals in the prevention and treatment of COVID-19. Cytoscape 3.7.2 software was used to build the network of "active ingredients of herbs-targets-disease", STRING platform was applied to construct the network of PPI, DAVID analysis platform to perform GO enrichment analysis and KEGG metabolism pathway of target genes, to survey the mechanism of preventing and treating COVID-19 with "Jinyinhua-Lianqiao". ResultsThere were 23 compounds from "Jinyinhua", 23 compounds from "Lianqiao", 204 effective targets of both, 44 targets related to COVID-19 were obtained via Venn diagram; it is found that IL-6, IL-1B, MAPK1, MAPK8, CXCL8, RELA, CCL2, IL10, ICAM1, IL-2, PTGS2, CASP3, MAPK14, STAT1, EGFR, FOS and IL-4 might be the targets of preventing and treating COVID-19 with "Jinyinhua-Lianqiao" through PPI. All 79 entries found in GO function analysis, involving the activity of transcription factor, receptor activity, cytokine activity, enzyme activity, and regulation of biosynthesis process. All 44 intersection targets of disease and drug were significantly enriched in 146 pathways in the analysis of KEGG pathway (P<0.01), covering inflammation, immunity, apoptosis, autophagy, hormone metabolism and tumor, and the pathways contained AGE-RAGE signaling pathway of diabetic complications, IL-17 signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, type C lectin receptor signaling pathway, HIF-1 signaling pathway, NF-κB signaling pathway and NOD-like receptor signaling pathway, in addition, participating in bacterial or viral infection pathways, such as Influenza A, hepatitis C, bronchocephalitis, tuberculosis, cytomegalovirus infection and EB virus infection. Meanwhile, these pathways possibly were the basis of the prevention and treatment of COVID-19 with "Yinqiao" couplet medicinals. ConclusionThe study has primarily verified the mechanism of preventing and treating COVID-19 with "Jinyinhua- Lianqiao", the compatibility of "Jinyinhua-Lianqiao" possesses many active ingredients, which could develop antiviral effects, antimicrobial and anti-inflammatory effects, regulating immune function through many targets and pathways, thereby preventing and treating COVID-19.

相似文献/References:

[1]李赟,王彩弟,王建云,等.简约远程中医诊疗在新型冠状病毒肺炎隔离病区中的应用[J].西部中医药,2020,33(S1):1.
　LI Yun,WANG Caidi,WANG Jianyun,et al.The Application of Simple Remote TCM Diagnosis and Treatment to COVID-19 Quarantined Inpatient Area[J].Western Journal of Traditional Chinese Medicine,2020,33(06):1.
[2]宋忠阳,雍文兴,张利英,等.新型冠状病毒肺炎的中医临床特征与辨证论治——甘肃经验*[J].西部中医药,2020,33(S1):3.
　SONG Zhongyang,YONG Wenxing,ZHANG Liying,et al.The Experience of TCM Clinical Characteristics, Syndrome Differentiation and Treatment for COVID-19 in Gansu Province[J].Western Journal of Traditional Chinese Medicine,2020,33(06):3.
[3]杜洪霖,马战平△.西北地区新型冠状病毒肺炎的中医特点及防治*[J].西部中医药,2020,33(S1):5.
　DU Honglin,MA Zhanping.TCM Characteristics, the Prevention and Treatment of COVID-19 in Northwest China[J].Western Journal of Traditional Chinese Medicine,2020,33(06):5.
[4]潘文,李盛华,王晓萍,等.中医对新型冠状病毒肺炎的认识与防治探讨[J].西部中医药,2020,33(S1):7.
　PAN Wen,LI Shenghua,WANG Xiaoping,et al.On TCM Understanding, the Prevention and Treatment of COVID-19[J].Western Journal of Traditional Chinese Medicine,2020,33(06):7.
[5]杨海侠,张银萍△,杨长虹,等.新型冠状病毒肺炎疑似患者留观隔离期的护理体会[J].西部中医药,2020,33(S1):13.
[6]丁潇,邹忆怀△,辛大永,等.北京顺义地区新型冠状病毒肺炎的中医临床证候与CT表现[J].西部中医药,2020,33(S1):16.
　DING Xiao,ZOU Yihuai,XIN Dayong,et al.TCM Clinical Syndromes and CT Manifestations of COVID-19 in Shunyi District of Beijing[J].Western Journal of Traditional Chinese Medicine,2020,33(06):16.
[7]桑天庆,周红光△.中医药在新型冠状病毒肺炎疫情中的应用[J].西部中医药,2020,33(S1):18.
　SANG Tianqing,ZHOU Hongguang.TCM Applied to Epidemic Situation of COVID-19[J].Western Journal of Traditional Chinese Medicine,2020,33(06):18.
[8]闫向勇,李 俊,燕忠生△.武汉地区新型冠状病毒肺炎中医证候及病机特点[J].西部中医药,2020,33(S1):20.
　YAN Xiangyong,LI Jun,YAN Zhongsheng.On the Characteristics of TCM Patterns and the Pathogenesis of COVID-19 in Wuhan Region[J].Western Journal of Traditional Chinese Medicine,2020,33(06):20.
[9]曾建峰,李乐愚,缪灿铭,等.岭南道地药材在中山地区新型冠状病毒肺炎防治中的应用*[J].西部中医药,2020,33(S1):24.[doi:10.1056/NEJMoa-2001017]
　and Treatment of COVID-9 in Zhongshan Region.The Application of Lingnan Genuine Drugs to the Prevention[J].Western Journal of Traditional Chinese Medicine,2020,33(06):24.[doi:10.1056/NEJMoa-2001017]
[10]朱玉,黎玉婷,姚德蛟△.从中西医不同角度分析麻杏石甘汤治疗新型冠状病毒肺炎的作用[J].西部中医药,2020,33(S1):26.
　of Traditional Chinese Medicine and Western Medicine.The Functions of Maxing Shigan Tang in the Treatment for COVID-19 from the Angles[J].Western Journal of Traditional Chinese Medicine,2020,33(06):26.

备注/Memo

备注/Memo:
刘晴晴（1991—），女，硕士学位。研究方向：心血管疾病的中医药防治。国家自然科学基金（81973776）；国家中医药管理局第二批国家中医临床研究基地项目（［2018］131号）。
更新日期/Last Update: 2023-06-15